Navigation Links
Scientists create digital bacteria to forge advances in biomedical research

Scientists at the University of Chicago and Argonne National Laboratory have constructed a computer simulation that allows them to study the relationship between biochemical fluctuations within a single cell and the cell's behavior as it interacts with other cells and its environment.

The simulation, called AgentCell, has possible applications in cancer research, drug development and combating bioterrorism. Other simulations of biological systems are limited to the molecular level, the single-cell level or the level of bacterial populations. AgentCell can simultaneously simulate activity on all three scales, something its creators believe no other software can do.

"With AgentCell we can simulate the behavior of entire populations of cells as they sense their environment, respond to stimuli and move in a three-dimensional world," said Thierry Emonet, a Research Scientist in Philippe Cluzel's laboratory at the University of Chicago's Institute for Biophysical Dynamics.

Emonet and his colleagues have verified the accuracy of AgentCell in biological experiments. AgentCell now enables scientists rapidly to run test experiments on the computer, saving them valuable time in the laboratory later.

Emonet is the lead author of a paper announcing the development of AgentCell that was published in the June 1 issue of the semimonthly journal Bioinformatics. His co-authors are Argonne's Charles Macal and Michael North, and the University of Chicago's Charles Wickersham and Philippe Cluzel. The work was funded by the U.S. Department of Energy and the University of Chicago/Argonne National Laboratory Seed Grant Program.

AgentCell will be used to tackle a major goal in single-cell biology today: to document the connection between internal biochemical fluctuations and cellular behavior. "The belief is that these fluctuations are going to be reflected in the behavior of the cell as shown experimentally by John Spudich and Daniel Koshland in 1976,
'"/>

Source:University of Chicago


Page: 1 2 3

Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... you,ve owned a pet guppy, you know they often jump out ... jumped; many a parent has been stumped for an answer. ... how guppies are able to jump so far, and suggests why ... that controls animal behavior, decided to study jumping guppies while researching ...
... Electronics group have come up with a novel solution ... organic semiconductor industry today. Oana Jurchescu, an assistant professor ... high performance organic semiconductor ,spray paint, that can be ... This is a potentially game changing technology for a ...
... reduced mortality in a mouse model of the neurodegenerative ... according to a new study by researchers at the ... published online ahead of print in the journal ... for melatonin are found in the nerve cells, a ...
Cached Biology News:Why do guppies jump? 2High performance semiconductor spray paint could be a game changer for organic electronics 2Pitt team finds melatonin delays ALS symptom onset and death in mice 2
(Date:4/27/2015)... Philadelphia, PA (PRWEB) April 27, 2015 ... Phelix Therapeutics, the newest resident of the University ... Market Street in Philadelphia. , With a $4.5 ... of Health in hand, Phelix Therapeutics is ... is developing nutritional supplements. The company is developing first-in-class ...
(Date:4/27/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) ... 2015 of $226.5 million, down 6%.  Excluding currency ... The Company reported a fourth quarter GAAP net ... Adjusted net income, exclusive of transformation, restructuring and ... up 1%, and adjusted earnings per share were ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
(Date:4/24/2015)... 24, 2015 The South Dakota School ... have entered into an agreement to promote cooperation on ... agreement signed by the universities will encourage and promote ... other services particularly, though not exclusively, relating to sustainability, ... strengths and a similar set of values,” said Michael ...
Breaking Biology Technology:New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 31Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2
... - William Blair & Company 29th Annual Growth Stock Conference on ... Needham Life Sciences Conference on June 11 - , ... GPRO ) announced today that the Company will present at the ... at approximately 11:20 a.m. Central time (12:20 p.m. Eastern time) on ...
... Block The Attachment Of The Virus To The Nasal Membranes , ... Corporation (Pink Sheets: MNCN), an innovative, global wellness solutions company, announces ... hand carried and used as needed to form a mechanical barrier ... , , Peter Nash, Ph.D. and Chief Science Officer of ...
... June 4 Haemonetics Corporation (NYSE: HAE ) ... of Massachusetts has made a ruling in the Company,s lawsuit ... jury issued a verdict in favor of Haemonetics, finding that ... patent. The jury awarded Haemonetics $15.7 million in damages ...
Cached Biology Technology:Gen-Probe to Webcast Two Upcoming Investor Presentations 2Mach One Corporation Developing a Nasal, Hand Carried Product as Solution to Swine Flu (H1N1) Virus 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
Applications: ISH...
... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: